Back to News
Market Impact: 0.35
HUYABIO International Announces HBI-8000 and Nivolumab Combination Reduces the Risk of Disease Progression by 27% in Patients with Advanced Melanoma in Phase 3 Trial
Source: PR Newswire
Healthcare & Biotech
Oral HBI-8000 plus intravenous nivolumab significantly improved progression-free survival versus nivolumab alone, reducing the risk of disease progression or death by 27%. Median progression-free survival was 11.7 months; the article excerpt does not provide the comparator median or further trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna shares plunge after leak of partial cancer vaccine data
- Palmer Luckey teams with dire wolf billionaire Ben Lamm to launch $200 million Warhound, unleashing genetically engineered clone dogs of war
- Moderna's stock tumbles after reported leak of data for cancer vaccine
- Zai Lab raises $250 million in private placement financing
- Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data